Does Medicare Cover Zepbound? Routes, Costs, and the $50 Bridge
Medicare won't pay for Zepbound or Mounjaro for weight loss alone. Two routes exist: the GLP-1 Bridge at $50 per month (July 1, 2026–December 31, 2027, Zepbound KwikPen only) and regular Part D coverage for diabetes, sleep apnea, or fatty liver disease. Without coverage, the manufacturer discount price is $299.00.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Medicare will not pay for Zepbound or Mounjaro if the only reason you’re taking it is weight loss — federal law bars Medicare from covering drugs prescribed specifically for weight loss [9]. But there are two ways Medicare can help pay. The first is the Medicare GLP-1 Bridge, a temporary nationwide program that runs July 1, 2026 through December 31, 2027 and charges eligible Part D enrollees a $50 monthly copayment for certain GLP-1 drugs; Zepbound is covered under the Bridge only in its KwikPen form [3][6][7]. The second is regular Part D coverage: if you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or fatty liver disease, your Medicare drug plan may already cover a GLP-1 for that condition [3][6][4]. If neither route fits, you’re paying out of pocket — the manufacturer exclusive discount price is $299.00, and Lilly’s direct-purchase out-of-pocket cost has been reported starting at $249 per fill [1][4].
What you actually pay depends on the route. On the Bridge, it’s $50 per month regardless of income, and that $50 does not count toward your Part D deductible or yearly out-of-pocket limit [6]. On regular Part D coverage, your cost depends on your plan’s formulary tier and pharmacy, and once your covered drug spending reaches the 2026 annual out-of-pocket cap of $2,100, your plan pays the full cost of covered drugs for the rest of the year [1].
| Route | Who it’s for | What you pay | Dates |
|---|---|---|---|
| Medicare GLP-1 Bridge | Eligible Part D enrollees without diabetes, sleep apnea, or fatty liver disease | $50 per month, no matter your income [3][6] | July 1, 2026 – December 31, 2027 [3][6][7] |
| Regular Part D coverage | People with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease | Plan copay or coinsurance, up to the $2,100 annual cap [1] | Ongoing, plan by plan [4] |
| Cash / discount | Anyone | Manufacturer exclusive discount price $299.00, or Lilly direct-purchase starting at $249 per fill [1][4] | Varies |
Why won’t Medicare cover a GLP-1 for weight loss alone?
Federal law prohibits Medicare from covering medications specifically for weight loss, while state Medicaid programs have more flexibility [9]. That’s why Medicare does not cover Zepbound — or other GLP-1s — for weight loss under standard Part D [4].
The Bridge is a short-term demonstration that sits separate from regular Part D coverage [9]. A proposed change to Medicare for 2026 that would have offered wider coverage of anti-obesity medications has not been implemented [4][9].
On the Medicaid side, coverage is shrinking rather than growing: as of January 2026, 13 states cover GLP-1s in Medicaid, down from 16 states in 2025 [9].
Does Medicare cover Mounjaro for type 2 diabetes?
Mounjaro and Zepbound both contain tirzepatide, but coverage follows the approved indication, not the active ingredient. Zepbound is available only as a brand-name medication, given as one injection under the skin once a week, and it is FDA-approved for obesity and weight management and for moderate-to-severe obstructive sleep apnea — not diabetes — so Medicare does not cover Zepbound for diabetes [1][4]. If you have type 2 diabetes, Medicare’s own guidance says to contact your Medicare drug plan, because it may already cover a GLP-1 drug for you [3][6].
One thing that will not help: Lilly’s Mounjaro Savings Card. It excludes anyone enrolled in Medicare, Medicare Part D, Medicare Advantage, Medigap, Medicaid, VA, DoD, TRICARE, or any state prescription drug assistance program [2]. The card’s advertised price — as little as $25 for up to a 3-month fill, where a month means 28 days and up to 4 pens — is for people with commercial insurance only [2].
If your plan does cover a GLP-1 for diabetes, the Medicare Prescription Payment Plan (M3P) can make the bills easier to manage. It’s free, it spreads your covered Part D drug costs into fixed monthly payments over the plan year, and you can opt in at any time [2].
Does Medicare cover Zepbound for sleep apnea?
It may. Zepbound is the first and only FDA-approved medication for moderate-to-severe obstructive sleep apnea, and it’s meant to be used along with a reduced-calorie diet and increased physical activity [4]. The FDA approved it for that use on December 20, 2024 [4].
Medicare Part D — or a Medicare Advantage plan that includes Part D coverage — may cover Zepbound if you have an obstructive sleep apnea diagnosis and a BMI of 27 or higher [4]. Prior authorization or other eligibility requirements may apply [4]. The diagnosis has to come from a doctor, typically after a sleep study that a physician reviews [4].
Two limits matter here. First, Medicare does not cover Zepbound for central sleep apnea [4]. Second, if you have moderate-to-severe sleep apnea, you are disqualified from the GLP-1 Bridge — Medicare’s position is that your Part D plan should cover the drug for that condition instead [3][6].
Your cost under this route depends entirely on your plan’s formulary tier and the pharmacy you use. Check your plan’s member portal or call the plan’s customer service line to find out what Zepbound would cost you [4]. No coverage rate has been published by CMS, and percentages circulating online are estimates, not verified data.
What does the Medicare GLP-1 Bridge cover, and what does the $50 include?
The Bridge covers three drugs: Foundayo (tablet), Wegovy (injection or tablet), and Zepbound KwikPen only [3][6]. The single-dose Zepbound pen and Zepbound vials are not covered [3][6]. Mounjaro is not on the Bridge drug list at all [3][6].
The copayment is $50 per month regardless of your income level [6]. It’s paid at the pharmacy for a one-month supply — for Zepbound KwikPen, one month is 28 days, and one pen holds all 4 weekly doses [5][6].
A few things the $50 does not do:
- It does not count toward your Part D deductible or your yearly out-of-pocket limit [6].
- Bridge drugs are not eligible for the Medicare Prescription Payment Plan [6].
- Pen needles are sold separately and are not included with the KwikPen [5].
The $50 is a program copayment for eligible Part D enrollees — not a retail or cash price for the drug.
Who qualifies for the Medicare GLP-1 Bridge?
The program has four requirements, and the health criteria must be true when GLP-1 therapy starts [3].
1. Part D drug coverage through an eligible plan type. That includes a standalone Medicare drug plan (PDP), a Medicare Advantage coordinated care plan with drug coverage (HMO, HMOPOS, and Local and Regional PPO plans), a Special Needs Plan (SNP), an employer or union group waiver plan (EGWP), or the Limited Income Newly Eligible Transition (LI NET) program [3][6]. You’re not eligible if your only Medicare coverage is through a private fee-for-service plan, a cost contract plan, or a PACE organization [5][6].
2. No GLP-1 already paid for by the Medicare drug plan, for any reason [3][6]. For this program, GLP-1s are defined as products containing semaglutide, tirzepatide, orforglipron, dulaglutide, or liraglutide [6].
3. No type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease [3][6]. If you have any of these, your Part D plan may already cover a GLP-1 for that condition [3][6].
4. Age 18 or older, plus one of these BMI thresholds:
| BMI | Additional requirement |
|---|---|
| 35 or higher | None [3][6] |
| 30 or higher | At least one of: diastolic heart failure (HFpEF), uncontrolled high blood pressure, or chronic kidney disease stage 3a or higher [3][6] |
| 27 or higher | At least one of: prediabetes, a previous heart attack or stroke, or symptomatic blocked arteries in your legs or arms (peripheral artery disease) [3][6] |
How do I actually get a Bridge fill?
The process runs through your doctor and your pharmacy:
- Your provider sends a prescription to the pharmacy and completes a prior authorization when requested [3]. The prescription must specify KwikPen — not the single-dose pen or the vial [5].
- Your provider must certify that you’re using the drug as part of a lifestyle program focused on diet and exercise [3].
- The pharmacy may ask for your Medicare Number (MBI) or the last 4 digits of your Social Security number to process the prescription [3][5][6].
- The pharmacy routes the claim using the Bridge information: BIN 028918, PCN MEDDGLP1BR, Group Name/ID GLP1Bridge [5]. LillyDirect Pharmacy can also fill Bridge prescriptions for home delivery [5].
- Medicare mails you a letter confirming the drug is covered. The prior authorization approval or denial also arrives by mail and can take several days [3][5][6].
Once approved, your prior authorization is valid through December 31, 2027 — including refills and dose changes — unless you switch to a different GLP-1 [3][5][6].
For eligibility questions or to check a prior authorization’s status, call 1-800-MEDICARE (1-800-633-4227), or TTY 1-877-486-2048. Medicare also has an eligibility questionnaire at medicare.gov/coverage/weight-loss-drugs [3][5][6].
What is the BALANCE model, and does it change 2027 coverage?
BALANCE — short for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth — is a CMS Innovation Center model in which CMS negotiates prices and coverage terms directly with GLP-1 manufacturers on behalf of state Medicaid agencies and Medicare Part D plan sponsors [7]. Its drug list includes all formulations of Mounjaro, Ozempic, Rybelsus, and Wegovy, plus Foundayo and the KwikPen formulation of Zepbound [7].
Novo Nordisk and Eli Lilly have agreed to participate at a $245 net price per 30-day supply for 2027 [9]. The model was planned to run January 1, 2027 through December 31, 2031, but it only goes into effect if a critical mass — at least 80% of Part D sponsors — chooses to participate [9]. CMS was set to notify Part D sponsor applicants whether that threshold was met by April 30, 2026 [9]. Application deadlines were April 20, 2026 for Part D plans, July 31, 2026 for state Medicaid programs, and January 8 for manufacturers [9].
Here’s the key point for Medicare: according to CMS’s FAQ, BALANCE is not launching in Medicare in 2027 [7]. Instead, the Bridge has been extended through December 31, 2027 so CMS can collect GLP-1 utilization data to share with Part D sponsors ahead of any potential implementation of BALANCE in Part D [7]. On the Medicaid side, states can join from May 2026 through January 1, 2027, and no participating state had been named on the CMS model page as of its August 14, 2026 update [7].
Lilly described the intended design differently in a March 9, 2026 statement: from January 1, 2027, Zepbound, Mounjaro, and orforglipron would be available through participating Part D plans, with most beneficiaries capped at $50 per month after the deductible is met and cost sharing limited to $245 per month plus a dispensing fee before the deductible [8]. Lilly also noted cost sharing would vary for a small number of basic Part D plans [8]. That describes the design if BALANCE launches in Part D — which, per CMS, it is not doing in 2027 [7]. The model’s stage is currently listed by CMS as “Announced” [7].
What do I pay if I have to buy Zepbound without coverage?
If you don’t qualify for the Bridge and your plan won’t cover the drug, you’re paying out of pocket. Zepbound’s average retail price is $587.01, and the manufacturer exclusive discount price is $299.00 — about 49% off [1]. Separately, Lilly’s direct-purchase out-of-pocket cost has been reported starting at $249 per fill, with roughly 100,000 people per month buying Zepbound from Lilly’s website [4].
A few rules and alternatives to know:
- You cannot combine GoodRx with Medicare, but you can use GoodRx instead of your insurance if it gives you a lower price [1].
- TrumpRx.gov lists cash prices, but you can’t buy drugs there. TrumpRx and other discount cards aren’t creditable coverage, and purchases made with them don’t count toward your Medicare deductible or out-of-pocket maximum [3].
- Medicare also points to manufacturer patient assistance programs, state pharmaceutical assistance programs, and mail-order pharmacy pricing as other ways to save [3].
- Extra Help (the Low-Income Subsidy) can cut Part D premiums, deductibles, and copays if your income and assets fall below certain limits [1].
- For covered drugs, a 90-day supply may lower your cost [1].
What should I do next, and when should I re-check?
Two calls answer most of the questions above. The plan’s pharmacy benefits line can confirm whether Zepbound or Mounjaro is on the formulary, and for which indication [4]. Medicare’s eligibility questionnaire at medicare.gov/coverage/weight-loss-drugs, or 1-800-MEDICARE, can confirm Bridge status [3].
Coverage is worth re-checking each fall, because plans can change their formularies, premiums, and copays from year to year [1]. The Annual Notice of Change should arrive by September 30, and open enrollment runs October 15 to December 7 — the annual window for switching plans [1]. The Medicare Plan Finder at medicare.gov lets you enter your drugs and compare plan coverage side by side [1].
The Bridge’s end date under the current program terms is December 31, 2027 [3][7].
Sources
- GoodRx. Zepbound Medicare coverage and co-pay details.
- Eli Lilly and Company. Savings & coverage | Mounjaro (tirzepatide).
- Medicare.gov. Weight loss drugs.
- Sleep Foundation. Does Medicare cover Zepbound for sleep apnea?
- Eli Lilly and Company. Medicare Part D coverage | Zepbound (tirzepatide).
- Medicare.gov. Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month. What you need to know for July 1, 2026.
- Centers for Medicare & Medicaid Services. BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model.
- Eli Lilly and Company. Updated: Lilly’s statement on the CMMI BALANCE Model for GLP-1 medicines and Medicare GLP-1 Bridge Model. March 9, 2026.
- Advisory Board. Will CMS’ new BALANCE model make GLP-1s more affordable? April 15, 2026.
- TRICARE Newsroom. Q&A: TRICARE For Life coverage of weight loss medications.
- Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge.
- Eli Lilly and Company. FDA approves Lilly’s Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. August 28, 2026.
- Centers for Medicare & Medicaid Services. BALANCE Model request for applications: Part D plan sponsors. March 2026.
Frequently asked questions
Does Medicare cover Zepbound for weight loss at all?
No. Federal law bars Medicare from covering drugs prescribed specifically for weight loss, so standard Part D won't pay for Zepbound or any other GLP-1 for weight loss alone. The exception is the temporary Medicare GLP-1 Bridge, which charges eligible Part D enrollees $50 per month for Zepbound KwikPen from July 1, 2026 through December 31, 2027.
Is Mounjaro covered when it's for diabetes?
Possibly. If you have type 2 diabetes, Medicare's guidance is to contact your drug plan, because it may already cover a GLP-1 for that condition. Mounjaro is not on the Bridge drug list, and Lilly's Mounjaro Savings Card excludes anyone enrolled in Medicare, Medicare Part D, Medicare Advantage, or Medigap.
What does the Bridge $50 copay include, and does it count toward the Part D cap?
The $50 covers a one-month (28-day) supply of a covered GLP-1 — for Zepbound, one KwikPen holds all 4 weekly doses. It does not count toward your Part D deductible or your yearly out-of-pocket limit, and Bridge drugs aren't eligible for the Medicare Prescription Payment Plan. Pen needles are sold separately.
Can I use the Bridge if I have sleep apnea or diabetes?
No. Having type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease disqualifies you from the Bridge, because your Part D plan may already cover a GLP-1 for those conditions. For sleep apnea specifically, Part D or a Medicare Advantage plan with drug coverage may cover Zepbound with an OSA diagnosis and a BMI of 27 or higher.
Which Zepbound device does the Bridge cover?
Only the KwikPen. The Bridge does not cover the single-dose Zepbound pen or Zepbound vials, so the prescription must specify KwikPen. One KwikPen contains all 4 weekly doses for the month, and it requires pen needles that are sold separately.
Do Medicare Advantage plans count for the Bridge?
Medicare Advantage coordinated care plans with drug coverage do — including HMO, HMOPOS, and Local and Regional PPO plans — along with Special Needs Plans and employer/union group waiver plans. You're not eligible if your only Medicare coverage is through a private fee-for-service plan, a cost contract plan, or a PACE organization.
Does Lilly's savings card work with Medicare?
No. The Mounjaro Savings Card excludes anyone enrolled in Medicare, Medicare Part D, Medicare Advantage, Medigap, Medicaid, VA, DoD, TRICARE, or state drug assistance programs. Its advertised $25 price for up to a 3-month fill applies only to people with commercial insurance that covers Mounjaro.
What BMI do I need to qualify for the Bridge?
The program requires a BMI of 35 or higher with no other conditions, a BMI of 30 or higher with certain heart failure, uncontrolled high blood pressure, or stage 3a-plus kidney disease, or a BMI of 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. The criteria must be met when GLP-1 therapy starts.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.